Dose-dense chemotherapy in advanced ovarian cancer

The Lancet

Volumn 374, Issue 9698, 2009, Pages 1303-1305

  Bookman, Michael A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; ALOPECIA; ANTIANGIOGENIC THERAPY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHRONOTHERAPY; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; JAPANESE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; OPTIMAL DRUG DOSE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 70349859988     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61305-2     Document Type: Note

References (14)

1. Katsumata N., Yasuda M., Takahashi F., et al., for the Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet (2009) 10.1016/S0140-6736(09)61157-0 published online Sept 20.
2. du Bois A., Quinn M., Thigpen T., et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16 suppl 8 (2005) viii7-viii12
3. Vasey P.A., Jayson G.C., Gordon A., et al., on behalf of the Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 (2004) 1682-1691
4. Bookman M.A., Brady M.F., McGuire W.P., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27 (2009) 1419-1425
5. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12 (1994) 2654-2666
6. Spriggs D.R., Brady M.F., Vaccarello L., et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25 (2007) 4466-4471
7. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101 (2006) 436-440
8. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358 (2008) 1663-1671
9. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26 (2008) 1642-1649
10. Lau D., Guo L., Gandara D., Young L.J., and Xue L. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?. Anticancer Drugs 15 (2004) 871-875
11. Omura G.A., Brady M.F., Look K.Y., et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an Intergroup study. J Clin Oncol 21 (2003) 2843-2848
12. Guminski A.D., Harnett P.R., and deFazio A. Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line-a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 48 (2001) 229-234
13. Armstrong D.K., Bundy B., Wenzel L., et al., for the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
14. ICON7. Overview (Feb 16, 2009). http://www.ctu.mrc.ac.uk/icon7/overview.asp (accessed July 27, 2009).